| US 7,468,379 B2 | ||
| Inhibition of osteolytic lesions by SRC kinase inhibitors | ||
| Bryant G. Darnay, Houston, Tex. (US); Janet E. Price, Missouri City, Tex. (US); Ann Poblenz, Seattle, Wash. (US); and Moshe Talpaz, Houston, Tex. (US) | ||
| Assigned to The Board of Regents of the University of Texas System, Austin, Tex. (US) | ||
| Filed on Jun. 16, 2006, as Appl. No. 11/455,272. | ||
| Claims priority of provisional application 60/691933, filed on Jun. 17, 2005. | ||
| Prior Publication US 2007/0004748 A1, Jan. 04, 2007 | ||
| Int. Cl. A61K 31/47 (2006.01) | ||
| U.S. Cl. 514—313 | 15 Claims |
1. A method of inhibiting bone resorption comprising, providing to a subject with pathological bone resorption a therapeutically
effective amount of a compound of the formula
 n is an integer from 1-3;
X is N, CH, provided that when X is N, n is 2 or 3;
R is an alkyl of 1 to 3 carbon atoms;
R(1) is 2,4-diC1, 5-OMe; 2,4-diC1; 3,4,5-tri-OMe; 2-Cl,5-OMe; 2-Me, 5-OMe; 2,4-diMe; 2,4-diMe-5-OMe, 2,4-diC1, 5-OEt;
R(2) is an alkyl of 1 to 2 carbon atoms, or a pharmaceutically acceptable salts thereof.
|